|
|
|
MIRA INFORM REPORT
|
Report No. : |
501667 |
|
Report Date : |
04.04.2018 |
IDENTIFICATION DETAILS
|
Name : |
RARITAN PHARMACEUTICALS INCORPORATED |
|
|
|
|
Registered Office : |
8 Joanna Court, East Brunswick, NJ,08816,
USA |
|
|
|
|
Country : |
United States |
|
|
|
|
Financials (as on) : |
2016 [Summarized] |
|
|
|
|
Date of Incorporation : |
20.02.2002 |
|
|
|
|
Legal Form : |
Corporation |
|
|
|
|
Line of Business : |
Subject develops, manufactures, and markets generic and niche OTC
medicines, medical devices, consumer products, and therapeutic cosmetics. |
|
|
|
|
No. of Employees : |
150 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd January
2017)
|
MIRA’s Rating : |
A+ |
|
Credit Rating |
Explanation |
Rating Comments |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
-- |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.09.2017) |
Current Rating (31.12.2017) |
|
United States |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
UNITED STATES - ECONOMIC OVERVIEW
The US has the most technologically powerful economy in the world, with
a per capita GDP of $57,300. US firms are at or near the forefront in technological
advances, especially in computers, pharmaceuticals, and medical, aerospace, and
military equipment; however, their advantage has narrowed since the end of
World War II. Based on a comparison of GDP measured at purchasing power parity
conversion rates, the US economy in 2014, having stood as the largest in the
world for more than a century, slipped into second place behind China, which
has more than tripled the US growth rate for each year of the past four
decades.
In the US, private individuals and business firms make most of the
decisions, and the federal and state governments buy needed goods and services
predominantly in the private marketplace. US business firms enjoy greater
flexibility than their counterparts in Western Europe and Japan in decisions to
expand capital plant, to lay off surplus workers, and to develop new products.
At the same time, businesses face higher barriers to enter their rivals' home
markets than foreign firms face entering US markets.
Long-term problems for the US include stagnation of wages for
lower-income families, inadequate investment in deteriorating infrastructure,
rapidly rising medical and pension costs of an aging population, energy
shortages, and sizable current account and budget deficits.
The onrush of technology has been a driving factor in the gradual
development of a "two-tier" labor market in which those at the bottom
lack the education and the professional/technical skills of those at the top
and, more and more, fail to get comparable pay raises, health insurance
coverage, and other benefits. But the globalization of trade, and especially
the rise of low-wage producers such as China, has put additional downward
pressure on wages and upward pressure on the return to capital. Since 1975,
practically all the gains in household income have gone to the top 20% of
households. Since 1996, dividends and capital gains have grown faster than
wages or any other category of after-tax income.
Imported oil accounts for nearly 55% of US consumption and oil has a
major impact on the overall health of the economy. Crude oil prices doubled
between 2001 and 2006, the year home prices peaked; higher gasoline prices ate
into consumers' budgets and many individuals fell behind in their mortgage
payments. Oil prices climbed another 50% between 2006 and 2008, and bank
foreclosures more than doubled in the same period. Besides dampening the
housing market, soaring oil prices caused a drop in the value of the dollar and
a deterioration in the US merchandise trade deficit, which peaked at $840
billion in 2008. Because the US economy is energy-intensive, falling oil prices
since 2013 have alleviated many of the problems the earlier increases had
created.
The sub-prime mortgage crisis, falling home prices, investment bank
failures, tight credit, and the global economic downturn pushed the US into a
recession by mid-2008. GDP contracted until the third quarter of 2009, making
this the deepest and longest downturn since the Great Depression. To help
stabilize financial markets, the US Congress established a $700 billion
Troubled Asset Relief Program (TARP) in October 2008. The government used some
of these funds to purchase equity in US banks and industrial corporations, much
of which had been returned to the government by early 2011. In January 2009,
Congress passed and President Barack OBAMA signed a bill providing an
additional $787 billion fiscal stimulus to be used over 10 years - two-thirds
on additional spending and one-third on tax cuts - to create jobs and to help
the economy recover. In 2010 and 2011, the federal budget deficit reached
nearly 9% of GDP. In 2012, the Federal Government reduced the growth of
spending and the deficit shrank to 7.6% of GDP. US revenues from taxes and
other sources are lower, as a percentage of GDP, than those of most other
countries.
Wars in Iraq and Afghanistan required major shifts in national resources
from civilian to military purposes and contributed to the growth of the budget
deficit and public debt. Through 2014, the direct costs of the wars totaled
more than $1.5 trillion, according to US Government figures.
In March 2010, President OBAMA signed into law the Patient Protection
and Affordable Care Act, a health insurance reform that was designed to extend
coverage to an additional 32 million Americans by 2016, through private health
insurance for the general population and Medicaid for the impoverished. Total
spending on healthcare - public plus private - rose from 9.0% of GDP in 1980 to
17.9% in 2010.
In July 2010, the president signed the DODD-FRANK Wall Street Reform and
Consumer Protection Act, a law designed to promote financial stability by
protecting consumers from financial abuses, ending taxpayer bailouts of
financial firms, dealing with troubled banks that are "too big to fail,"
and improving accountability and transparency in the financial system - in
particular, by requiring certain financial derivatives to be traded in markets
that are subject to government regulation and oversight.
In December 2012, the Federal Reserve Board (Fed) announced plans to
purchase $85 billion per month of mortgage-backed and Treasury securities in an
effort to hold down long-term interest rates, and to keep short-term rates near
zero until unemployment dropped below 6.5% or inflation rose above 2.5%. In late
2013, the Fed announced that it would begin scaling back long-term bond
purchases to $75 billion per month in January 2014 and further reduce them as
conditions warranted; the Fed ended the purchases during the summer of 2014. In
2014, the unemployment rate dropped to 6.2%, and continued to fall to 5.5% by
mid-2015, the lowest rate of joblessness since before the global recession
began; inflation stood at 1.7%, and public debt as a share of GDP continued to
decline, following several years of increases. In December 2015, the Fed raised
its target for the benchmark federal funds rate by 0.25%, the first increase
since the recession began. With US GDP growth below 2%, the Fed opted to raise
rates three times since then, and in mid-June 2017, the range for the target
rate stood at 1% to 1.25%.
|
Source
: CIA |
STATUTORY
INFORMATION
|
|
|
Legal Name: |
RARITAN PHARMACEUTICALS INCORPORATED |
|
Trade Names: |
RARITAN PHARMACEUTICALS INCORPORATED |
|
ID: |
0100872149 |
|
Date Created: |
2002 |
|
Date Incorporated: |
02/20/2002 |
|
Legal Address: |
8 Joanna Court ,East Brunswick,NJ,08816 , USA |
|
Operative Address: |
8 Joanna Court, East Brunswick, NJ, 08816, USA |
|
Telephone: |
732-432-8200 |
|
Fax: |
732-432-8255 |
|
Legal Form: |
Corporation |
|
Email: |
marketing@raritanpharm.com |
|
Registered in: |
NEW JERSEY |
|
Website: |
www.raritanpharm.com |
|
Contact: |
VIN NAYAK - President |
|
Staff: |
150 |
|
Activity: |
NAICS 1: Pharmaceutical Preparation Manufacturing SIC 1: Pharmaceutical Preparations |
|
|
|
|
Banks: |
BANK OF AMERICA |
|
|
|
|
History: |
Raritan Pharmaceuticals Inc. was founded in 2002 and is based in East
Brunswick, New Jersey. |
|
|
|
|
Key Developments: |
Raritan Pharmaceuticals Inc. Recall Homeopathic Products Containing Belladonna
Extract Due to the Possibility of the Presence of Belladonna Alkaloids Nov 24 16 Raritan Pharmaceuticals is voluntarily recalling homeopathic products
containing belladonna extract due to the potential for variation in the
content of belladonna extract in the products. The U.S. FDA has tested some
products and recovered varying levels of belladonna extract content from what
is declared on the label. Raritan Pharmaceuticals is a contract manufacturer
of these products for Homeolab USA that supplies the belladonna blends to
Raritan Pharmaceuticals. The homeopathic products have a very small amount of
belladonna, a substance that can cause harm at larger doses. The company is
voluntarily recalling the product out of an abundance of caution. These products
were distributed Nationwide. Consumers with any product being recalled should
stop using the product. Consumers with questions regarding this recall can
contact Raritan Pharmaceuticals by phone at 1-866-467-2748. No other Homeolab or Raritan products are affected. |
|
|
|
PRINCIPAL
ACTIVITY
|
|
|
|
Raritan Pharmaceuticals Inc. develops, manufactures, and markets
generic and niche OTC medicines, medical devices, consumer products, and
therapeutic cosmetics. |
|
Products/Services description: |
The company offers generic and niche OTC medicines, medical devices,
consumer products, and therapeutic cosmetics in the form of powders,
capsules, specialty liquids, gels, ointments, creams, and film-delivery
systems; and chewable, fast-dissolving, and swallowable tablets. |
|
Brands: |
DRX CHOICE EASYFIBER EZ FIBER |
|
Sales are: |
Wholesale |
|
Clients: |
The company sells its products through a network of retail chains and
drug distributors in the United States. |
|
Suppliers: |
Vovantis Laboratories Pvt Ltd Associated Capsules Pvt., Ltd. Cmc Machinery Alpha Pharma Daman Pvt Ltd |
|
Operations area: |
National and International |
|
The company imports from |
INDIA |
|
The company exports to |
The company exports to Europe, the Middle East, and South America. |
|
The subject employs |
150 employees |
|
Payments: |
Regular |
|
|
|
LOCATION
|
|
|
Headquarters : |
8 JOANNA COURT, EAST BRUNSWICK, NJ, 08816, USA |
|
Comments on Address: |
This business is located at 8 Joanna Ct, a commercial address in East
Brunswick, NJ. The industrial property has an estimated value of $2.41 million USD,
which is 255% higher than the $677,745 United States dollars average for
industrial properties in the area. When the building was last assessed in
2012, the assessment value was $2.3 million USD. With 178,240 square feet of space, this building is one of the largest
industrial properties in the 08816 zip code. The average industrial property
in the area has around 2,956 square feet. |
|
Branches: |
No other branches were found. |
|
Related Companies: |
No related companies were found. |
|
|
|
GROUP
STRUCTURE AND SUBSIDIARY COMPANIES
|
|
|
Listed at the stock exchange: |
NO |
|
Capital: |
NA |
|
Shareholders: |
The company does not disclose information on shareholders. The
following information has been obtained through private sources and could not
be confirmed: The major holder of this company is: VIN NAYAK |
|
Management: |
VIN NAYAK – President SULTAN RESHAMWALA – Vice President |
|
|
|
FINANCIAL
INFORMATION
|
|
|
|
The company does not make its financial
statements public. The following information has been provided by private
sources: |
|
|
|
|
USD 2016 |
|
|
Gross Sales |
50.000.000 |
|
Cash flow |
Normal |
|
|
|
LEGAL
FILINGS
|
|
|
|
|
|
PATENTS |
No found. |
|
|
|
|
GOVERNMENT CONTRACTS |
No records found. |
|
|
|
|
CASES |
RARITAN PHARMACEUTICALS, INC. v. AMERICAN ENTERPRISES LLC Plaintiff: RARITAN PHARMACEUTICALS, INC. Defendant: AMERICAN ENTERPRISES LLC Case Number: 3:2014cv01159 Filed: February 21, 2014 Court: New Jersey District Court Office: Trenton Office County: Middlesex Referring Judge: Lois H. Goodman Presiding Judge: Freda L. Wolfson Nature of Suit: Personal Injury: Health Care/Pharmaceutical Personal
Injury Product Liability Cause of Action: 28:1332 Diversity-Product Liability Jury Demanded By: Plaintiff CNS Inc. v. Raritan Pharmaceuticals Inc. Plaintiff: CNS Inc. Defendant: Raritan Pharmaceuticals Inc. Case Number: 1:2008cv00910 Filed: December 5, 2008 Court: Delaware District Court Office: Patent Office County: XX US, Outside State Presiding Judge: Unassigned Judge Nature of Suit: Plaintiff Cause of Action: Federal Question Jury Demanded By: 35:271 Patent Infringement |
|
|
|
|
TRADEMARKS |
DRX CHOICE Over-The-Counter Drugs and Nutritional Supplements Owned by: Raritan Pharmaceuticals Inc. Serial Number: 78431682 EASYFIBER Over-The-Counter Drugs in the nature of pharmaceutical preparations for
treating gastrointestinal disorders, heart disease… Owned by: Raritan Pharmaceuticals Inc. Serial Number: 78466227 EZ FIBER Over-the-counter drugs and nutritional supplements Owned by: Raritan Pharmaceuticals Inc. Serial Number: 78574339 |
|
|
|
|
RENEWAL HISTORY |
Annual Report Month: FEBRUARY Last Annual Report Filed: 05/25/2016 Year: 2016 |
|
|
|
|
UCC |
No records found. |
|
|
|
|
OFAC Sanctions List Search |
The company is not listed in the OFAC list. |
|
|
|
|
SUMMARY |
|
|
|
Founded in 2002, Raritan Pharmaceuticals Inc is a mid-sized
organization in the pharmaceutical preparation company’s industry located in
East Brunswick, NJ. It has 150 full time employees and generates an estimated $50 million
USD in annual revenue. The company operates nationally and internationally,
mainly importing from India. It is ACTIVE in business with no negative
records. |
|
|
|
RISK
INFORMATION
|
|
|
DEBTS |
Controlled |
|
PAYMENTS |
Regular |
|
CASH FLOW |
Normal |
|
STATUS |
Active |
|
|
|
|
INTERVIEW |
|
|
NAME |
Paul |
|
POSITION |
Sales |
|
COMMENTS |
He confirmed the name of the company, the address of the headquarters
and location, the date of creation of the company, the number of employees
and the name of the President. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 65.02 |
|
|
1 |
INR 91.45 |
|
Euro |
1 |
INR 80.09 |
|
US Dollar |
1 |
INR 65.10 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.